-
About UsBPL is a high-tech China-Cuba joint venture among first group engaged in the development, production and sales of monoclonal antibodies in China.
-
S&TInternational-standard humanized monoclonal antibody preparation processes and large-scale, continuous mammalian cell culture technology.
-
Research and DevelopmentChina has developed nivolumab, a humanized monoclonal antibody drug (trade name: TaiXinSheng), for the treatment of malignant tumors.
-
BlogIntegrating industry-related media coverage as well as the company’s various activities and updates.
-
Join UsBoasting a postdoctoral research workstation and diverse career opportunities, we sincerely invite talented individuals from all fields to join Baite.
-
What is the mechanism behind TaiXinSheng's cancer treatment?
Category:
Patient Consultation
Author:
Source:
Release date:
2016-01-12
Certain tumor cells exhibit overexpression of EGFR (epidermal growth factor receptor) on their surface. EGFR is closely linked to tumor proliferation and invasion, and patients with EGFR overexpression typically have a poorer prognosis. Taisinsheng specifically blocks the EGFR signaling pathway, inhibiting tumor growth and invasion, thereby exerting its anti-tumor effects.
Related News
Biotech pharmaceutical co., Ltd
Email: cooperation@biotechplc.com
BD Dept: bd@biotechplc.com
Address：NO.2 Rongjing East Street, Beijing Economic and Technological Development Area, Beijing 100176
Biotech pharmaceutical co., Ltd
E-mail：
Tel：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： BIOTECH PHARMACEUTICAL CO., LTD
表单验证提示文本： Content cannot be empty!
循环体没有内容时： Sorry, no matching items were found.
CSS / JS 文件放置地